Literature DB >> 29368165

Antibiotic resistance in E. coli isolates from patients with urinary tract infections presenting to the emergency department.

Florian Hitzenbichler1, Michaela Simon2, Thomas Holzmann2, Michael Iberer3, Markus Zimmermann4, Bernd Salzberger3, Frank Hanses3,4.   

Abstract

PURPOSE: Escherichia coli urine isolates from patients presenting to the emergency department at a German tertiary care hospital were retrospectively analyzed from January 2015-March 2017 to determine antibiotic resistance patterns and patient risk factors for resistance.
METHODS: Uncomplicated urinary tract infection (UTI) was defined as UTI in the otherwise healthy patient without relevant co-morbidities and complications. Patients were assumed to have UTI if diagnosis was made by the attending physician with conclusive dipstick results. For subgroup analysis, only patients with symptoms suggestive for UTI documented in their records were included.
RESULTS: 228 patients with a UTI diagnosed by the attending physician with E. coli isolated in urine culture were included. 154/228 patients had documented symptomatic UTI, 57/154 had uncomplicated infection, 76/154 patients had cystitis, and 124/154 were female. Resistance rates of uncomplicated UTI in symptomatic patients were: ciprofloxacin 10.5%, cotrimoxazole 15.8%, amoxicillin/clavulanic acid 5.3%, nitrofurantoin 0% (CLSI MICs). Previous hospitalization in the last 3 months (including patients living in a long-term care facility) was significantly correlated with resistance to ciprofloxacin, cotrimoxazole and amoxicillin/clav. Previous hospitalization was a strong predictor of resistance to ciprofloxacin and cotrimoxazole in multivariate analysis also. Other risk factors correlated with resistance were hematological malignancy (for cotrimoxazole) and renal transplantation (for ciprofloxacin).
CONCLUSIONS: Cotrimoxazole is still an alternative for treating uncomplicated cystitis. Previous hospitalization in the last 3 months was a strong predictor of resistance to cotrimoxazole and ciprofloxacin. Other risk factors which might help guide empirical therapy are hematological malignancy and renal transplantation.

Entities:  

Keywords:  Ciprofloxacin; Cotrimoxazole; E. coli; Resistance rates; Risk factors; Urinary tract infection

Mesh:

Year:  2018        PMID: 29368165     DOI: 10.1007/s15010-018-1117-5

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections.

Authors:  Tommaso Cai; Gabriella Nesi; Sandra Mazzoli; Francesca Meacci; Paolo Lanzafame; Patrizio Caciagli; Liliana Mereu; Saverio Tateo; Gianni Malossini; Cesare Selli; Riccardo Bartoletti
Journal:  Clin Infect Dis       Date:  2015-08-12       Impact factor: 9.079

Review 2.  The comeback of trimethoprim in France.

Authors:  F Caron; V Wehrle; M Etienne
Journal:  Med Mal Infect       Date:  2017-01-02       Impact factor: 2.152

3.  Trimethoprim prescription and subsequent resistance in childhood urinary infection: multilevel modelling analysis.

Authors:  Mary A Duffy; Virginia Hernandez-Santiago; Gillian Orange; Peter G Davey; Bruce Guthrie
Journal:  Br J Gen Pract       Date:  2013-04       Impact factor: 5.386

4.  Incidence of urinary tract infections and antibiotic resistance in the outpatient setting: a cross-sectional study.

Authors:  Louise Rossignol; Sophie Vaux; Sylvie Maugat; Alexandre Blake; Roxane Barlier; Beate Heym; Yann Le Strat; Thierry Blanchon; Thomas Hanslik; Bruno Coignard
Journal:  Infection       Date:  2016-05-27       Impact factor: 3.553

Review 5.  Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials.

Authors:  Angela Huttner; Els M Verhaegh; Stephan Harbarth; Anouk E Muller; Ursula Theuretzbacher; Johan W Mouton
Journal:  J Antimicrob Chemother       Date:  2015-06-11       Impact factor: 5.790

6.  Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use.

Authors:  M Sundqvist; P Geli; D I Andersson; M Sjölund-Karlsson; A Runehagen; H Cars; K Abelson-Storby; O Cars; G Kahlmeter
Journal:  J Antimicrob Chemother       Date:  2009-11-08       Impact factor: 5.790

7.  Clinical uncertainties in the approach to long term care residents with possible urinary tract infection.

Authors:  David A Nace; Paul J Drinka; Christopher J Crnich
Journal:  J Am Med Dir Assoc       Date:  2014-02       Impact factor: 4.669

8.  Antimicrobial susceptibility of Escherichia coli in uncomplicated cystitis in the emergency department: is the hospital antibiogram an effective treatment guide?

Authors:  S Christian Smith; Christopher Bazzoli; Irving Chung; Andrew Johnson; Daniel R Martin
Journal:  Acad Emerg Med       Date:  2015-08       Impact factor: 3.451

9.  Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.

Authors:  Kurt G Naber; Giancarlo Schito; Henry Botto; Juan Palou; Teresita Mazzei
Journal:  Eur Urol       Date:  2008-05-21       Impact factor: 20.096

10.  Comparison of antibiotic susceptibility of Escherichia coli in urinary isolates from an emergency department with other institutional susceptibility data.

Authors:  Catherine Zatorski; Jeanne A Jordan; Sara E Cosgrove; Mark Zocchi; Larissa May
Journal:  Am J Health Syst Pharm       Date:  2015-12-15       Impact factor: 2.637

View more
  8 in total

1.  Novel 5-Nitrofuran-Activating Reductase in Escherichia coli.

Authors:  Vuong Van Hung Le; Ieuan G Davies; Christina D Moon; David Wheeler; Patrick J Biggs; Jasna Rakonjac
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Comparison of approaches for source attribution of ESBL-producing Escherichia coli in Germany.

Authors:  Sara Perestrelo; Guido Correia Carreira; Lars Valentin; Jennie Fischer; Yvonne Pfeifer; Guido Werner; Judith Schmiedel; Linda Falgenhauer; Can Imirzalioglu; Trinad Chakraborty; Annemarie Käsbohrer
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

3.  A comparative evaluation of antibacterial activities of imidazolium-, pyridinium-, and phosphonium-based ionic liquids containing octyl side chains.

Authors:  Rabia Hassan; Muhammad Asad Asghar; Mudassir Iqbal; Arshemah Qaisar; Uzma Habib; Bashir Ahmad
Journal:  Heliyon       Date:  2022-05-25

Review 4.  Antibiotic Resistance Among Uropathogenic Escherichia coli.

Authors:  Barbara Kot
Journal:  Pol J Microbiol       Date:  2019-12-05

5.  Surveillance of antibiotic resistance among uropathogens in Aljouf region northern Saudi Arabia.

Authors:  Ibrahim Taher; Abdulrahman Almaeen; Hassan Aljourfi; Eyad Bohassan; Ahmed Helmy; Eman El-Masry; Baraka Saleh; Nawaf Aljaber
Journal:  Iran J Microbiol       Date:  2019-12

6.  Molecular Characterization of Uropathogenic Escherichia coli Reveals Emergence of Drug Resistant O15, O22 and O25 Serogroups.

Authors:  Ruta Prakapaite; Frederic Saab; Rita Planciuniene; Vidmantas Petraitis; Thomas J Walsh; Ruta Petraitiene; Rasa Semoskaite; Rasa Baneviciene; Lilija Kalediene; Povilas Kavaliauskas
Journal:  Medicina (Kaunas)       Date:  2019-11-11       Impact factor: 2.430

7.  Clinical impact of multidrug-resistant bacteria in older hospitalized patients with community-acquired urinary tract infection.

Authors:  Manuel Madrazo; Ana Esparcia; Ian López-Cruz; Juan Alberola; Laura Piles; Alba Viana; José María Eiros; Arturo Artero
Journal:  BMC Infect Dis       Date:  2021-12-07       Impact factor: 3.090

8.  Trends in antibiotic resistance for over 700,000 Escherichia coli positive urinary tract infections over six years (2014-2019) from a university teaching hospital.

Authors:  Andrea Ong; Nitin Mahobia; Dave Browning; Matthew Schembri; Bhaskar K Somani
Journal:  Cent European J Urol       Date:  2021-05-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.